These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 9037282

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K, Lehnert M, Stettner H, Hubmer G.
    Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR, CaPSURE Investigators.
    Cancer; 2006 Apr 15; 106(8):1708-14. PubMed ID: 16544313
    [Abstract] [Full Text] [Related]

  • 5. Comparison of patient and spouse assessments of health related quality of life in men with metastatic prostate cancer.
    Sneeuw KC, Albertsen PC, Aaronson NK.
    J Urol; 2001 Feb 15; 165(2):478-82. PubMed ID: 11176400
    [Abstract] [Full Text] [Related]

  • 6. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
    Calais da Silva FE, Bono AV, Whelan P, Brausi M, Marques Queimadelos A, Martin JA, Kirkali Z, Calais da Silva FM, Robertson C.
    Eur Urol; 2009 Jun 15; 55(6):1269-77. PubMed ID: 19249153
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Endocrine treatment of prostate cancer.
    Tammela T.
    J Steroid Biochem Mol Biol; 2004 Nov 15; 92(4):287-95. PubMed ID: 15663992
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effect of androgen deprivation therapy on quality of life in Japanese men with prostate cancer.
    Kato T, Komiya A, Suzuki H, Imamoto T, Ueda T, Ichikawa T.
    Int J Urol; 2007 May 15; 14(5):416-21. PubMed ID: 17511724
    [Abstract] [Full Text] [Related]

  • 11. Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.
    Raina R, Pahalajani G, Agarwal A, Zippe C.
    Asian J Androl; 2007 Mar 15; 9(2):253-8. PubMed ID: 17334592
    [Abstract] [Full Text] [Related]

  • 12. Quality of life outcomes after brachytherapy for early stage prostate cancer.
    Brandeis JM, Litwin MS, Burnison CM, Reiter RE.
    J Urol; 2000 Mar 15; 163(3):851-7. PubMed ID: 10687991
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up.
    Bañez LL, Blake GW, McLeod DG, Crawford ED, Moul JW.
    BJU Int; 2009 Aug 15; 104(3):310-4. PubMed ID: 19239458
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T, Nishizawa K, Mitsumori K.
    Scand J Urol Nephrol; 2006 Aug 15; 40(3):198-203. PubMed ID: 16809259
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.